Pulmonary Arterial Hypertension


Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.

PAH is defined by >25 mmHg increase in pulmonary arterial blood pressure and a pulmonary capillary wedge pressure of 15 mmHg. If left untreated, PAH is fatal; it has a survival rate of just 34% after 5 years. Current therapies include stimulating the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) axis, improving the prostacyclin pathway or inhibiting the endothelin pathway.

Related Articles


Recognition, Diagnosis, and Management of Heart Failure with Preserved…

Meshal Soni, Edo Y Birati,

Citation: US Cardiology Review 2018;12(1):8–12.

Impact of Atrial Septal Defect on Hemodynamics

Saumil R Shah, Sergio Waxman, William H Gaasch,

Citation: US Cardiology Review 2017;11(2):72–4.

Pharmacologic Strategies for Management of Pulmonary Arterial Hypertension

Rebecca L Attridge, Rebecca D Moote, Deborah J Levine,

Citation: US Cardiology Review 2016;10(2):78–84

The Role of Oral Vasoactive Agents in the Treatment of Pulmonary Arterial…

Omar A Minai,

Citation: US Cardiology 2006;3(1):1–5